Discover
CTOR
Citius Oncology, Inc.
1.14
2 x 0.76
2 x 1.36
bid
ask
+
0.12
11.76%
2 @ 07:47 PM
1.12 -0.02 (1.75%)
| Ytd | 14.00% | |
| 1y | -34.86% |
1.01
day range
1.16
0.49
52 week range
2.03
| Open | 1.05 | Prev Close | 1.02 | Low | 1.01 | High | 1.16 | Mkt Cap | 120.57M |
| Vol | 337.51K | Avg Vol | 86.43K | EPS | -0.48 | P/E | N/A | Forward P/E | N/A |
| Beta | 3.52 | Short Ratio | 0.37 | Inst. Own | 0.70% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 0.74 | 200-d Avg | 0.89 | 1yr Est | 3.00 |
| Income Statement | |||
| Total Revenue | 1.49M | ||
| Revenues (USD) | 1.49M | ||
| Cost of Revenue | 491.84K | ||
| Gross Profit | 1.00M | ||
| Operating Expenses | 9.72M | ||
| Research and Development Expense | 218.50K | ||
| Selling, General and Administrative Expense | 4.22M | ||
| Operating Income | -8.72M | ||
| Interest Expense | 231.73K | ||
| Income Tax Expense | -107.35K | ||
| Net Income | -8.92M | ||
| Net Income Common Stock | -8.92M | ||
| Net Income Common Stock (USD) | -8.92M | ||
| Consolidated Income | -8.92M | ||
| Earnings per Basic Share | -0.08 | ||
| Earnings per Basic Share (USD) | -0.08 | ||
| Earnings per Diluted Share | -0.08 | ||
| Earning Before Interest & Taxes (EBIT) | -8.80M | ||
| Earning Before Interest & Taxes (USD) | -8.80M | ||
| Weighted Average Shares | 107.89M | ||
| Weighted Average Shares Diluted | 107.89M | ||
| Balance Sheet | |||
| Cash and Equivalents | 16.56M | ||
| Cash and Equivalents (USD) | 16.56M | ||
| Trade and Non-Trade Receivables | 686.24K | ||
| Current Assets | 42.71M | ||
| Total Assets | 112.09M | ||
| Total Debt | 10.21M | ||
| Current Liabilities | 58.79M | ||
| Debt Non-Current | 10.21M | ||
| Total Liabilities | 71.71M | ||
| Accumulated Retained Earnings (Deficit) | -105.11M | ||
| Shareholders Equity | 40.38M | ||
| Shareholders Equity (USD) | 40.38M | ||
| Assets Non-Current | 69.39M | ||
| Total Debt (USD) | 10.21M | ||
| Inventory | 22.63M | ||
| Liabilities Non-Current | 12.92M | ||
| Trade and Non-Trade Payables | 32.95M | ||
| Tax Liabilities | 2.71M | ||
| Cash Flow | |||
| Net Cash Flow from Financing | 18.64M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 13.93M | ||
| Capital Expenditure | -2.00M | ||
| Issuance (Purchase) of Equity Shares | 9.73M | ||
| Issuance (Repayment) of Debt Securities | 9.64M | ||
| Net Cash Flow from Investing | -2.00M | ||
| Net Cash Flow from Operations | -2.71M | ||
| Share Based Compensation | 3.56M | ||